Vivos Therapeutics (VVOS)
(Real Time Quote from BATS)
$2.23 USD
+0.05 (2.29%)
Updated May 16, 2024 02:26 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
VVOS 2.23 +0.05(2.29%)
Will VVOS be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for VVOS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for VVOS
Here Is Why Bargain Hunters Would Love Fast-paced Mover Vivos Therapeutics, Inc. (VVOS)
Here's Why Vivos Therapeutics, Inc. (VVOS) Could be Great Choice for a Bottom Fisher
VVOS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Looking for a Fast-paced Momentum Stock at a Bargain? Consider Vivos Therapeutics, Inc. (VVOS)
Vivos Therapeutics, Inc. (VVOS) Reports Q1 Loss, Tops Revenue Estimates
Phreesia (PHR) Reports Q1 Loss, Tops Revenue Estimates
Other News for VVOS
Vivos Therapeutics Inc (VVOS) Q1 2024 Earnings Call Transcript Highlights: Navigating ...
Vivos Therapeutics GAAP EPS of -$1.63, revenue of $3.4M
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Vivos Therapeutics Reports First Quarter 2024 Financial Results and Provides Operational Update